Tag Archives: Jason Mccarthy
Maxim Group Initiates a Buy Rating on Navidea (NAVB)
Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Navidea (NAVB – Research Report) yesterday and set a price target of $2. The company’s shares closed yesterday at $0.68. McCarthy commented: “We are initiating coverage of Buy
Coherus Biosciences (CHRS) Receives a Buy from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price target of $25. The company’s shares closed yesterday at $20.29. McCarthy wrote: “Coherus announced preliminary net
Cerecor Inc (CERC) Gets a Buy Rating from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Cerecor Inc (CERC – Research Report), with a price target of $10. The company’s shares opened today at $5.64. McCarthy said: “Cerecor reported positive Parkinson’s
Analysts’ Top Services Picks: OncoSec Medical (ONCS), Pareteum Corp (TEUM)
There’s a lot to be optimistic about in the Services sector as 2 analysts just weighed in on OncoSec Medical (ONCS – Research Report) and Pareteum Corp (TEUM – Research Report) with bullish sentiments. OncoSec Medical (ONCS) Maxim Group analyst
Maxim Group Thinks Intec Pharma Ltd’s Stock is Going to Recover
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Intec Pharma Ltd (NTEC – Research Report), with a price target of $12. The company’s shares opened today at $4.35, close to its 52-week low
BioNano Genomics Inc (BNGO) Gets a Buy Rating from Maxim Group
Maxim Group analyst Jason McCarthy maintained a Buy rating on BioNano Genomics Inc (BNGO – Research Report) yesterday and set a price target of $11. The company’s shares opened today at $2.69, close to its 52-week low of $2.50. McCarthy
